[go: up one dir, main page]

RU96119803A - COMBINED DRUG FOR CONTRACEPTION BASED ON NATURAL ESTROGENS - Google Patents

COMBINED DRUG FOR CONTRACEPTION BASED ON NATURAL ESTROGENS

Info

Publication number
RU96119803A
RU96119803A RU96119803/14A RU96119803A RU96119803A RU 96119803 A RU96119803 A RU 96119803A RU 96119803/14 A RU96119803/14 A RU 96119803/14A RU 96119803 A RU96119803 A RU 96119803A RU 96119803 A RU96119803 A RU 96119803A
Authority
RU
Russia
Prior art keywords
natural
daily doses
active substance
daily
dose
Prior art date
Application number
RU96119803/14A
Other languages
Russian (ru)
Other versions
RU2113849C1 (en
Inventor
Диттген Михаель
Фрике Забине
Хоффманн Херберт
Мооре Клаудиа
Этель Михаель
Остертаг Моника
Original Assignee
Йенафарм ГмбХ & Ко.КГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19540253A external-priority patent/DE19540253C2/en
Application filed by Йенафарм ГмбХ & Ко.КГ filed Critical Йенафарм ГмбХ & Ко.КГ
Application granted granted Critical
Publication of RU2113849C1 publication Critical patent/RU2113849C1/en
Publication of RU96119803A publication Critical patent/RU96119803A/en

Links

Claims (4)

1. Комбинированный препарат для концентрации, состоящий из многих ступеней, отличающийся тем, что первая ступень состоит из 2-4 ежедневных доз, причем каждая ежедневная доза как активное вещество состоит исключительно из природных эстрогенов, вторая ступень состоит из 22-16 ежедневных доз, причем каждая ежедневная доза как активное вещество содержит комбинацию из по крайней мере одного природного эстрогена и по крайней мере одного синтетического или природного гестагена, третья ступень состоит из 2-4 ежедневных доз, причем каждая ежедневная доза как активное вещество содержит исключительно природные экстрогены и каждая последующая ступень состоит из 2-4 ежедневных доз, причем каждая доза содержит в фармацевтическом отношении чистое плацебо.1. A combined preparation for concentration, consisting of many stages, characterized in that the first stage consists of 2-4 daily doses, each daily dose as an active substance consisting exclusively of natural estrogens, the second stage consists of 22-16 daily doses, each daily dose as an active substance contains a combination of at least one natural estrogen and at least one synthetic or natural progestogen, the third stage consists of 2-4 daily doses, and each daily the dose as an active substance contains exclusively natural estrogens and each subsequent step consists of 2-4 daily doses, and each dose contains a pharmaceutically pure placebo. 2. Комбинированный препарат по п.1, отличающийся тем, что вторая ступень состоит из 2 групп ежедневных доз, причем первая группа состоит из 5-3 ежедневных доз, а вторая группа - из 17-13 ежедневных доз и доля синтетических и природных гестагенов во второй группе превышает долю в первой группе. 2. The combined preparation according to claim 1, characterized in that the second stage consists of 2 groups of daily doses, the first group consisting of 5-3 daily doses, and the second group of 17-13 daily doses and the proportion of synthetic and natural progestogens in the second group exceeds the share in the first group. 3. Комбинированный препарат по пп.1 или 2, отличающийся тем, что экстрогенное активное вещество, которое после приема эстрадиола образует соединение эстардиола в организме, является коньюгированным конским экстрогеном или фитоэстрогеном. 3. The combined preparation according to claims 1 or 2, characterized in that the extrogenic active substance, which, after taking estradiol, forms an estradiol compound in the body, is a conjugated equine estrogen or phytoestrogen. 4. Комбинированный препарат по пп. 1-3, отличающийся тем, что эстрогенное активное вещество является природным прогестероном, медроксипрогестиронацетатом или другим синтетическим гестагеном. 4. The combined preparation according to paragraphs. 1-3, characterized in that the estrogenic active substance is natural progesterone, medroxyprogesterone acetate or other synthetic progestogen.
RU96119803/14A 1995-10-28 1996-09-27 Mixed preparation based on natural estrogens for contraception RU2113849C1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19540253.7-41 1995-10-28
DE19540253A DE19540253C2 (en) 1995-10-28 1995-10-28 Multi-phase preparation for contraception based on natural estrogens

Publications (2)

Publication Number Publication Date
RU2113849C1 RU2113849C1 (en) 1998-06-27
RU96119803A true RU96119803A (en) 1998-12-20

Family

ID=7776074

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96119803/14A RU2113849C1 (en) 1995-10-28 1996-09-27 Mixed preparation based on natural estrogens for contraception

Country Status (18)

Country Link
US (2) US6133251A (en)
EP (1) EP0770388B1 (en)
JP (1) JP3020880B2 (en)
CN (1) CN1137691C (en)
AT (1) ATE164312T1 (en)
CA (1) CA2188907C (en)
CZ (1) CZ290741B6 (en)
DE (3) DE19540253C2 (en)
DK (1) DK0770388T3 (en)
ES (1) ES2116804T3 (en)
FR (1) FR09C0018I2 (en)
HU (1) HU223753B1 (en)
LU (1) LU91643I2 (en)
NL (1) NL300381I2 (en)
PL (1) PL186339B1 (en)
RU (1) RU2113849C1 (en)
SI (1) SI0770388T1 (en)
SK (1) SK281709B6 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032756A1 (en) * 1995-10-28 2005-02-10 Michael Dittgen Multistage preparation for contraception based on natural estrogens
FR2754179B1 (en) 1996-10-08 1998-12-24 Theramex NOVEL HORMONONAL COMPOSITION AND ITS USE
WO2001030355A1 (en) 1999-10-25 2001-05-03 Laboratoire Theramex Contraceptive medicine based on a progestational agent and an oestrogen and preparation method
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
CA2267743C (en) 1999-03-30 2011-07-26 Robert F. Casper Low dose estrogen interrupted hormone replacement therapy
AU2005201151B2 (en) * 1999-03-30 2008-01-10 Jencap Research Ltd Low dose estrogen interrupted hormone replacement therapy
RS50262B2 (en) * 1999-08-31 2018-10-31 Bayer Pharma AG PHARMACEUTICAL COMBINATION OF ETHINYLESTRADIOL AND DROSPIRENONE FOR ADMINISTRATION AS CONTRACEPTIVE
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US7297688B2 (en) 2000-06-08 2007-11-20 Wyeth Starter kit for low dose oral contraceptives
NZ533242A (en) 2001-12-05 2007-11-30 Duramed Pharmaceuticals Inc Oral extended regime contraceptive package
TWI252111B (en) * 2001-12-14 2006-04-01 Solvay Pharm Gmbh Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
TW200403065A (en) * 2002-05-30 2004-03-01 Akzo Nobel Nv New etonogestrel esters
US20040072814A1 (en) 2002-10-11 2004-04-15 Solvay Pharmaceuticals Gmbh Method for obtaining a natural mixture of conjugated equine estrogens depleted in non-conjugated lipophilic compounds
AR041121A1 (en) * 2002-10-11 2005-05-04 Solvay Pharm Gmbh PROCEDURE FOR OBTAINING A NATURAL MIXTURE OF CONJUGATED STROGENS
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
DE102004019743B4 (en) * 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Multiphase preparation for contraception based on natural estrogen
ATE546144T1 (en) * 2005-10-13 2012-03-15 Bayer Pharma AG USE OF ESTRADIOLVALERATE IN COMBINATION WITH DIENOGEST FOR ORAL THERAPY OF DYSF UNCTIONAL UTERINE BLEEDING IN UNIT WITH ORAL CONTRACEPTION
EP1787649B1 (en) * 2005-10-13 2009-03-11 Bayer Schering Pharma Aktiengesellschaft Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
WO2007106264A2 (en) * 2006-03-02 2007-09-20 Warner Chilcott Company, Inc. Extended cycle multiphasic oral contraceptive method
EP1930010A1 (en) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Application of estradiol valerate or 17ß-estradiol in combination with dienogest for oral therapy to maintain and/or increase the female libido
RS62297B1 (en) 2011-11-23 2021-09-30 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (en) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． Natural combination hormone replacement therapy and therapy
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4292315A (en) * 1977-12-30 1981-09-29 Nichols Vorys Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system
US4390531A (en) * 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4921843A (en) * 1988-10-20 1990-05-01 Pasquale Samuel A Contraception system and method
IE62665B1 (en) * 1990-12-17 1995-02-22 Akzo Nv Contraceptive regimen
DE4104385C1 (en) * 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
DE4224534A1 (en) * 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Anti-ovulation agent for hormonal contraception
DE4308406C1 (en) * 1993-03-12 1994-06-16 Jenapharm Gmbh Contraceptive compsn. with reduced hormone dose and reduced side-effects - contg. synergistic mixt. of biogenic, synthetic oestrogen and gestagen
DE4339934C2 (en) * 1993-05-07 1995-05-24 Klaus Dr Med Umbreit Anti-ovulation agent for hormonal contraception
NL9301562A (en) * 1993-09-09 1995-04-03 Saturnus Ag Substitution therapy preparation.
DE4344462C2 (en) * 1993-12-22 1996-02-01 Schering Ag Composition for contraception
DE4429374C1 (en) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmaceutical preparations for contraception / hormone substitution with biogenic estrogen component

Similar Documents

Publication Publication Date Title
RU96119803A (en) COMBINED DRUG FOR CONTRACEPTION BASED ON NATURAL ESTROGENS
CA2188907A1 (en) Combination compound for contraception based on natural estrogen
FI103951B (en) Preventive System
ATE216241T1 (en) VERY LOW DOSE ORAL CONTRACEPTIVE WITH LESS MENSTRUAL BLEEDING AND DELAYED EFFECT
KR920011517A (en) Low Estrogen Oral Contraceptives
CA2356747A1 (en) Triphasic oral contraceptive
RU96115196A (en) COMPOSITION FOR CONTRACEPTION
DK365887D0 (en) COMBINATION DOSAGE FOR HORMONE TREATMENT OF WOMEN IN PRAE-MENOPAUSUS
PT99819A (en) PROCESS FOR THE MANUFACTURE OF ORAL CONTRACEPTIVES UNDERSTANDING PROGESTOGEN AND ESTROGEN
KR960706344A (en) MEANS AND METHOD FOR HORMONAL CONTRACEPTION AND / OR THE TREATMENT OF ACNE
EP0628312A1 (en) Anti-contraceptive composition
CL2011000017A1 (en) Use of a pharmaceutical composition comprising i) 0.5 to 3 mg of an estrogen selected from free estradiol, esterified estradiol and conjugated equine estrogens, ii) 1.5 to 3.75 of nomegestrol acetate, and iii) pharmaceutical excipients suitable for treating estrogen deficiencies in postmenopausal women (divisional application 1997-02114).
NZ333750A (en) Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
KR920011514A (en) Contraceptives containing only progestogens
KR970706004A (en) Hormonal Drugs and Their Use for the Treatment of Estrogen Deficiency (NOVEL HORMONAL MEDICAMENTS AND USE THEREOF FOR CORRECTING OESTROGEN DEFICIENCIES)
ATE278406T1 (en) ORAL CONTRACEPTIVE
Coutinho The vaginal contraceptive pill